Exudative Macular Degeneration Clinical Trial
Official title:
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD). Preliminary efficacy will be assessed by change from baseline in visual acuity, fluorescein leakage, retinal thickness and fibrosis, if detectable, based on fundus examination, fundus photography, fluorescein angiography and optical coherence tomography (OCT).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01835067 -
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
| Completed |
NCT01473251 -
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
|
N/A | |
| Recruiting |
NCT05093374 -
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
|
Phase 4 | |
| Completed |
NCT01617148 -
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
|
Phase 4 | |
| Completed |
NCT01535950 -
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT02287298 -
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
|
N/A | |
| Active, not recruiting |
NCT03803631 -
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
|